Sinil Pharmaceutical has been growing earnings at an average annual rate of 8.8%, while the Pharmaceuticals industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 7% per year. Sinil Pharmaceutical's return on equity is 4.5%, and it has net margins of 8.5%.
How Sinil Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A012790 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
82,183
6,951
24,690
3,133
31 Dec 25
80,564
7,531
22,670
2,694
30 Sep 25
80,972
11,311
21,364
2,704
30 Jun 25
80,978
11,475
21,146
2,803
31 Mar 25
85,921
12,654
22,085
2,423
31 Dec 24
89,440
14,301
22,036
2,802
30 Sep 24
91,699
15,066
19,922
4,096
30 Jun 24
96,516
15,763
20,924
3,447
31 Mar 24
90,064
13,505
20,546
2,958
31 Dec 23
89,135
13,641
19,938
2,979
30 Sep 23
86,210
12,624
20,187
3,521
30 Jun 23
81,163
11,613
19,383
3,521
31 Mar 23
83,914
13,444
18,738
3,521
31 Dec 22
80,007
12,157
18,032
3,264
30 Sep 22
75,971
11,067
18,492
743
30 Jun 22
72,082
10,343
17,181
838
31 Mar 22
66,435
8,229
15,768
833
31 Dec 21
61,754
6,679
15,735
195
30 Sep 21
60,177
5,201
16,124
294
30 Jun 21
59,435
5,407
16,167
426
31 Mar 21
59,323
6,494
16,198
740
31 Dec 20
61,438
7,544
16,195
785
30 Sep 20
63,736
8,359
14,821
1,003
30 Jun 20
63,613
8,072
15,069
775
31 Mar 20
63,547
8,017
15,220
466
31 Dec 19
60,648
7,257
14,446
530
30 Sep 19
57,397
7,115
14,992
316
30 Jun 19
54,252
5,497
14,109
1,005
31 Mar 19
53,241
4,767
13,836
1,029
31 Dec 18
53,277
5,714
13,809
853
30 Sep 18
52,442
6,385
13,492
824
30 Jun 18
52,867
7,888
13,426
135
31 Mar 18
51,369
8,293
12,936
108
31 Dec 17
50,942
8,198
12,865
93
30 Sep 17
50,545
7,731
13,107
73
30 Jun 17
49,387
8,376
12,783
73
31 Mar 17
49,158
8,840
13,017
75
31 Dec 16
50,212
9,360
12,389
64
30 Sep 16
49,134
9,432
11,803
5
30 Jun 16
48,151
9,352
11,502
9
31 Mar 16
46,964
9,117
11,331
29
31 Dec 15
44,703
8,764
11,109
24
30 Sep 15
45,240
9,405
10,925
74
30 Jun 15
46,805
9,905
11,099
77
Quality Earnings: A012790 has high quality earnings.
Growing Profit Margin: A012790's current net profit margins (8.5%) are lower than last year (14.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A012790's earnings have grown by 8.8% per year over the past 5 years.
Accelerating Growth: A012790's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A012790 had negative earnings growth (-45.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.5%).
Return on Equity
High ROE: A012790's Return on Equity (4.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/29 18:58
End of Day Share Price
2026/06/29 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sinil Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.